RRM2 and pancreatic adenocarcinoma: While resistance to gemcitabine was associated with both RRM1 and RRM2 overexpression [17], [56], small interfering RNA targeting the RRM2 catalytic subunit, reported in [57], enhanced the chemosensitivity to gemcitabine of pancreatic adenocarcinoma in vitro and in vivo.